{"id":35153,"date":"2026-02-25T09:12:00","date_gmt":"2026-02-25T14:12:00","guid":{"rendered":"https:\/\/www.wellable.co\/blog\/?p=35153"},"modified":"2026-07-31T09:14:44","modified_gmt":"2026-07-31T13:14:44","slug":"fda-crackdowns-shaping-the-glp-1-market","status":"publish","type":"post","link":"https:\/\/www.wellable.co\/blog\/fda-crackdowns-shaping-the-glp-1-market\/","title":{"rendered":"FDA Crackdowns Shaping the GLP-1 Market"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">In this episode, Nick and Geoff discuss the rapid adoption of GLP-1 drugs; recent FDA crackdowns on compound pharmacies; and the implications for employers, consumers, and the healthcare industry. They explore market dynamics, regulatory challenges, and the potential economic impact of GLP-1s.<\/p>\n\n\n\n<div class=\"video-embed\" style=\"position:relative;padding-bottom:56.25%;height:0;\">\n<iframe src=\"https:\/\/www.youtube.com\/embed\/Ms4ga-R56V0?si=qv598HgMcOuUZmzs\" title=\"\nFDA Crackdowns Shaping the GLP-1 Market\" style=\"position:absolute;width:100%;height:100%;top:0;left:0;\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen=\"\">\n  <\/iframe>\n<\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<div class=\"row justify-content-between\">\n<div class=\"cs-btn-light text-center mb-4 col-12 col-md-6 pr-md-4\">\n  <a class=\"cs-button d-flex align-items-center justify-content-center w-100\" href=\"https:\/\/podcasts.apple.com\/us\/podcast\/fda-crackdowns-shaping-the-glp-1-market\/id1869414001?i=1000751582340\" target=\"_blank\" style=\"gap: 8px\">\n\n<img decoding=\"async\" src=\"https:\/\/www.wellable.co\/blog\/wp-content\/uploads\/2026\/03\/Apple-Podcasts-logo.png\" alt=\"Apple podcast\" loading=\"lazy\" class=\"h-auto\" style=\"width: 24px\">\n\n<span style=\"font-size: 20px\">Listen on Apple Podcasts<\/span>\n<\/a>\n<\/div>\n\n<div class=\"cs-btn-light text-center mb-4 col-12 col-md-6 pl-md-4\">\n  <a class=\"cs-button d-flex align-items-center justify-content-center gap-3 w-100\" href=\"https:\/\/open.spotify.com\/episode\/5TCIEg2wHyzXJMXz0pr16f?si=8rU2b7blT_K4029tKEIBDw\" target=\"_blank\" style=\"gap: 8px\">\n\n<img decoding=\"async\" src=\"https:\/\/www.wellable.co\/blog\/wp-content\/uploads\/2026\/03\/Spotify_White_Logo.png\" alt=\"Apple podcast\" loading=\"lazy\" class=\"h-auto pr\" style=\"width: 24px\">\n<span style=\"font-size: 20px\">Listen on Spotify<\/span>\n\n<\/a>\n<\/div>\n<\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n<div style=\"border: 1px solid rgb(0 0 0 \/ 0.1); padding: 25px 25px 10px; border-radius: 8px; box-shadow: 0 4px 6px -1px rgb(0 0 0 \/ 0.1), 0 2px 4px -2px rgb(0 0 0 \/ 0.1);\">\n<h3 id=\"h-pressed-for-time-here-s-a-quick-summary\" class=\"wp-block-heading nitoc\">Short on time? Here are the key takeaways:<\/h3>\n<ul>\n<li>1 in 5 employers cover GLP-1s for weight loss, 12% of US adults report currently using the medication<\/li>\n<li>FDA crackdown on compound pharmacies and active ingredients will affect GLP-1 supply, as compound versions surged amid shortages<\/li>\n<li>Market demand is strong, and employers will continue to face decisions on eligibility for coverage as supply tightens<\/li>\n<li>Broader economic impact of GLP-1s is only beginning to unfold, with early ripple effects already appearing in industries like airlines and food as consumer behavior and health trends shift<\/li>\n<\/ul>\n<\/div>\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" class=\"wp-block-heading\" id=\"episode-summary\">Episode Summary<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" class=\"wp-block-heading\" id=\"state-of-the-union-how-fast-glp-1-adoption-is-growing\">State of the Union: How Fast GLP-1 Adoption Is Growing<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Nick opens with a state of the union on GLP-1 adoption, pulling from a November 2025 Kaiser Family Foundation study: 18% of US adults have used a GLP-1 drug at some point, and 12% are currently using one. Given how quickly the category has been growing, both hosts agree the real numbers today are almost certainly higher.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">What&#8217;s more interesting than the raw adoption number is the breakdown of why people are using these drugs. Of current users, 45% have diabetes\u2014the original use case for the drug class\u201429% have heart disease, and 23% are using GLP-1s for being overweight or obese. Only 3% fall into a catch-all &#8220;other&#8221; category. Nick flags that 3% as surprisingly low, given how much media attention centers on GLP-1s as a weight-loss and vanity drug. He suspects the &#8220;other&#8221; bucket is where most of that vanity-driven usage actually lives, and that it may simply be undercounted in survey data. He points to former Secretary of State Mike Pompeo&#8217;s dramatic and widely noted weight loss as one example of a public figure whose transformation has fueled public curiosity about non-clinical GLP-1 use.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Geoff draws a parallel to a topic the podcast covers constantly: AI. Like AI, GLP-1s are a phenomenon that shows up simultaneously as a personal, consumer-facing story and a workplace, employer-facing one. On the employer side, Geoff cites the Peterson-KFF Health System Tracker: just under 19% of firms with 200 or more employees currently cover GLP-1s for weight loss, and about a third of those employers require some type of lifestyle management program or clinical intervention before granting access. That combination of rising personal demand and inconsistent employer coverage sets up exactly why a supply-side shock, like the one the FDA just delivered, matters so much.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" class=\"wp-block-heading\" id=\"the-fdas-compounding-crackdown\">The FDA&#8217;s Compounding Crackdown<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The core news driving this episode: the FDA announced a crackdown last week on an active pharmaceutical ingredient used in GLP-1 drugs. To understand why that matters, Nick walks through what a compound pharmacy actually does. Compound pharmacies are allowed to operate without FDA approval in two common scenarios: creating customized versions of a medication for a patient&#8217;s specific needs (a different dose, a cream instead of a pill), or filling a legitimate supply gap when demand for an FDA-approved drug outpaces what&#8217;s available on the market.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">GLP-1s have fallen squarely into that second bucket for years. Novo Nordisk, the pioneer of the category, makes Ozempic (an injection) and Wegovy (currently the only FDA-approved oral GLP-1 pill for weight loss). Because demand for these drugs has consistently outstripped supply, compound pharmacies stepped in to fill the gap using ingredients that remained on the FDA&#8217;s approved compounding list\u2014no FDA approval required, as long as the ingredient stayed on that list.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Hims &amp; Hers built a multi-billion-dollar, publicly traded telehealth business partly on this model, offering a compounded GLP-1 injection and preparing to launch a compounded pill. That changed the moment the FDA removed the relevant active ingredient from the compounding list. Once an ingredient comes off that list, compound pharmacies can no longer legally produce it without going through FDA approval. Hims &amp; Hers has already announced it will not bring its planned pill to market, and rumors are circulating that the company&#8217;s existing injection product may be pulled as well. Nick notes he doesn&#8217;t see how the company avoids pulling it if the ingredient in that product is the one that was removed.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Geoff adds that &#8220;compound pharmacy&#8221; was a new term for him too, and that the episode is a good reminder of just how much demand for GLP-1s has outpaced not just availability, but affordability. Compounded versions have often been the more accessible, lower-cost entry point for consumers paying fully out of pocket. Removing that option doesn&#8217;t just affect one company; it removes a meaningful source of overall market supply.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" class=\"wp-block-heading\" id=\"the-impact-on-employer-coverage-and-pharmacy-spend\">The Impact on Employer Coverage and Pharmacy Spend<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">With compounded supply shrinking, Geoff raises the question that matters most for HR and benefits leaders: does this increase pressure on employers to expand coverage? Demand for GLP-1s has already been building for years, largely because access and cost have been the primary barriers, not interest.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The numbers back this up. Per the Peterson-KFF Health System Tracker, 64%, almost two-thirds, of employers say GLP-1 drug coverage has moderately or significantly impacted their prescription drug spending. That&#8217;s already a meaningful cost signal for benefits teams, even before compounded alternatives become harder to access.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Nick admits he was surprised that only about a third of employers currently require a lifestyle management or clinical support program as a condition of GLP-1 coverage. On paper, that kind of requirement should appeal to cost-conscious employers: adding a hurdle before coverage kicks in naturally reduces the number of employees who complete every step and ultimately claim the benefit, which lowers overall pharmacy spend. But Nick argues that framing misses the bigger opportunity. Research consistently shows that the best outcomes from GLP-1 use come from pairing the drug with real lifestyle support: nutrition guidance tailored to a changing appetite and metabolism, and structured physical activity to offset the muscle loss that often accompanies rapid weight loss on these drugs. Done well, a lifestyle management program isn&#8217;t just a cost gatekeeper. It&#8217;s the difference between a good outcome and the best possible one.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Nick predicts more employers will adopt these programs going forward, for two reasons: some purely to manage cost, but others because they genuinely want better outcomes for employees using the drug. He suspects the low one-third adoption rate so far is less about employers rejecting the concept and more about the complexity of rolling out both a new drug benefit and a companion program at the same time. As GLP-1 coverage matures, expect employers who already cover the drug to retroactively layer in lifestyle management as a next step.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Geoff points to another driver behind employer decision-making that goes beyond direct health outcomes: satisfaction. The same KFF research found that employers who currently cover GLP-1s for weight loss rate that coverage as important or very important to employee satisfaction. And that data predates any potential supply crunch from the FDA&#8217;s compounding restrictions. If compounded, lower-cost access becomes harder to find in the consumer market, pressure on employers to fill that gap through their benefits plan is only likely to intensify.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" class=\"wp-block-heading\" id=\"the-ripple-effect-from-prescription-spend-to-airline-fuel-bills\">The Ripple Effect: From Prescription Spend to Airline Fuel Bills<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Nick closes with what he considers the single most striking GLP-1 statistic he&#8217;s come across: a Jefferies analysis estimating that domestic US airlines could save roughly $580 million annually in fuel costs, driven purely by a reduction in average passenger weight tied to GLP-1 adoption. The estimate assumes a 10% reduction in average passenger weight translates to a 1.5% reduction in fuel costs, a small percentage that, multiplied across tens of billions of dollars in annual industry fuel spend, adds up to hundreds of millions in additional profit. None of that comes from airlines improving operations or aircraft manufacturers building more fuel-efficient planes. It comes entirely from a shift happening in an entirely different industry.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">That&#8217;s the broader point Nick and Geoff want listeners to sit with. If AI weren&#8217;t dominating the news cycle every single day, GLP-1s would likely be the biggest ongoing business story of the last several years. Nick goes further, arguing that over the next two to four years, GLP-1s&#8217; cumulative impact on the economy could exceed AI&#8217;s, at least in the near term, even if AI&#8217;s long-run impact on the labor market ultimately proves larger. And with only 19% of employers currently covering these drugs and just 12% of US adults currently using them, both hosts agree: this is still early. The ripple effects, for employers, for adjacent industries, and for the broader economy, are only beginning to show up.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" class=\"wp-block-heading\" id=\"frequently-asked-questions\">Frequently Asked Questions<\/h2>\n\n\n\n    <section class=\"faq-section\">\n      <div class=\"faq-accordion\">\n\n        \n        <div class=\"faq-item card card-faq\">\n          <button \n            class=\"faq-question\" \n            data-target=\"faq_1\"\n            type=\"button\"\n          >\n            What did the FDA just do regarding GLP-1 drugs?            <span class=\"icon\"><\/span>\n          <\/button>\n\n          <div id=\"faq_1\" class=\"faq-answer\">\n            <p class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\" data-sourcepos=\"69:1-69:509;11248-11756\">The FDA removed an active pharmaceutical ingredient used in GLP-1 drugs from its list of ingredients that compound pharmacies can legally use without FDA approval. Once an ingredient comes off that list, any compound pharmacy producing a version of the drug with that ingredient must obtain FDA approval to continue, something most compounders are not positioned to do. This directly disrupted companies like Hims &amp; Hers that had built consumer-facing GLP-1 businesses around compounded versions of the drug.<\/p>\n          <\/div>\n        <\/div>\n\n        \n        <div class=\"faq-item card card-faq\">\n          <button \n            class=\"faq-question\" \n            data-target=\"faq_2\"\n            type=\"button\"\n          >\n            What is a compound pharmacy, and why does it matter for GLP-1s?            <span class=\"icon\"><\/span>\n          <\/button>\n\n          <div id=\"faq_2\" class=\"faq-answer\">\n            <p class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\" data-sourcepos=\"73:1-73:473;11827-12299\">A compound pharmacy is permitted to produce medications without full FDA approval in specific circumstances: when customizing a drug for an individual patient&#8217;s needs, or when there&#8217;s a genuine supply shortage of an FDA-approved product. Because demand for GLP-1s has outpaced supply for years, compound pharmacies became a significant source of market access, particularly for consumers seeking a lower-cost, direct-to-consumer option outside employer-sponsored coverage.<\/p>\n          <\/div>\n        <\/div>\n\n        \n        <div class=\"faq-item card card-faq\">\n          <button \n            class=\"faq-question\" \n            data-target=\"faq_3\"\n            type=\"button\"\n          >\n            How has this affected Hims &amp; Hers?            <span class=\"icon\"><\/span>\n          <\/button>\n\n          <div id=\"faq_3\" class=\"faq-answer\">\n            <p class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\" data-sourcepos=\"77:1-77:358;12341-12698\">Hims &amp; Hers, a publicly traded telehealth company that built part of its business on compounded GLP-1 products, announced it will not bring its previously planned GLP-1 pill to market following the FDA&#8217;s decision. Rumors also suggest the company&#8217;s existing compounded injection product could be pulled as well, though that has not been officially confirmed.<\/p>\n          <\/div>\n        <\/div>\n\n        \n        <div class=\"faq-item card card-faq\">\n          <button \n            class=\"faq-question\" \n            data-target=\"faq_4\"\n            type=\"button\"\n          >\n            What percentage of US adults are currently using GLP-1 drugs?            <span class=\"icon\"><\/span>\n          <\/button>\n\n          <div id=\"faq_4\" class=\"faq-answer\">\n            <p class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\" data-sourcepos=\"81:1-81:229;12767-12995\">According to a November 2025 Kaiser Family Foundation study, 18% of US adults have used a GLP-1 drug at some point, and 12% are currently using one. Given how quickly adoption has been growing, current figures are likely higher.<\/p>\n          <\/div>\n        <\/div>\n\n        \n        <div class=\"faq-item card card-faq\">\n          <button \n            class=\"faq-question\" \n            data-target=\"faq_5\"\n            type=\"button\"\n          >\n            How many employers currently cover GLP-1s, and do they require anything in return?            <span class=\"icon\"><\/span>\n          <\/button>\n\n          <div id=\"faq_5\" class=\"faq-answer\">\n            <p class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\" data-sourcepos=\"85:1-85:289;13085-13373\">Roughly 19% of firms with 200 or more employees currently cover GLP-1 drugs for weight loss, according to the Peterson-KFF Health System Tracker. About one-third of those employers require employees to complete a lifestyle management or clinical support program before accessing coverage.<\/p>\n          <\/div>\n        <\/div>\n\n        \n        <div class=\"faq-item card card-faq\">\n          <button \n            class=\"faq-question\" \n            data-target=\"faq_6\"\n            type=\"button\"\n          >\n            Why are airlines relevant to a conversation about GLP-1s?            <span class=\"icon\"><\/span>\n          <\/button>\n\n          <div id=\"faq_6\" class=\"faq-answer\">\n            <p class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\" data-sourcepos=\"89:1-89:359;13438-13796\">A Jefferies analysis estimated that widespread GLP-1 adoption could reduce average passenger weight enough to save US domestic airlines approximately $580 million annually in fuel costs. It&#8217;s a striking example of how a healthcare trend with no direct connection to aviation can still produce a meaningful financial impact on a completely unrelated industry.<\/p>\n          <\/div>\n        <\/div>\n\n        \n        <div class=\"faq-item card card-faq\">\n          <button \n            class=\"faq-question\" \n            data-target=\"faq_7\"\n            type=\"button\"\n          >\n            Should employers add a lifestyle management program alongside GLP-1 coverage?            <span class=\"icon\"><\/span>\n          <\/button>\n\n          <div id=\"faq_7\" class=\"faq-answer\">\n            <p class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\" data-sourcepos=\"93:1-93:438;13881-14318\">The hosts note that research consistently shows the best outcomes from GLP-1 use come from combining the drug with structured lifestyle support, particularly nutrition guidance and physical activity to help offset the muscle loss that often accompanies rapid weight loss. Rather than viewing these programs purely as a cost-control gatekeeper, employers may get better results by treating them as a genuine complement to the drug itself.<\/p>\n          <\/div>\n        <\/div>\n\n        \n      <\/div>\n    <\/section>\n\n    \n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" class=\"wp-block-heading\" id=\"full-episode-transcript\"><strong style=\"color: transparent; visibility: hidden; opacity: 0;\">Full Episode Transcript<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n    <section class=\"faq-section toc-helper-accordion\">\n      <div class=\"faq-accordion\">\n\n        \n        <div class=\"custom-accordion-item\">\n          <button \n            class=\"faq-question\" \n            data-target=\"transcript_1\"\n            type=\"button\"\n          >\n            <h2 id=\"full-episode-transcript\"><strong>Full Episode Transcript<\/strong><\/h2>\n            <span class=\"icon\"><\/span>\n          <\/button>\n\n          <div id=\"transcript_1\" class=\"faq-answer\">\n            <p class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\" data-sourcepos=\"97:1-97:440;14348-14787\"><strong>Nick:<\/strong> Welcome to the Wellable Weekly Podcast, where we talk about key topics and trends at the intersection of wellbeing, technology, and HR. I&#8217;m Nick, along with my good friend, Geoff. If you&#8217;re paying attention to the FDA, last week was pretty big news around some crackdowns on compound pharmacies and GLP-1s. To be honest, I&#8217;m kind of shocked we&#8217;re this far into the year without a single episode on GLP-1s. Better late than never.<\/p>\n<p class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\" data-sourcepos=\"99:1-99:461;14789-15249\">Before we get into it, I think it&#8217;s always helpful to do a state of the union, especially for something changing as quickly as GLP-1s. On adoption, the Kaiser Family Foundation released a really good study back in November of 2025. A couple of data points: 18% of US adults have used GLP-1s, and 12% are currently using the drug. Given how fast this category is growing, and it&#8217;s been a few months since that report, I imagine those numbers have already moved.<\/p>\n<p class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\" data-sourcepos=\"101:1-101:587;15251-15837\">What&#8217;s also interesting is why people are using these drugs. The original use case for GLP-1s was diabetes. Of the 12% currently using them, 45% are using it for diabetes, 29% for heart disease, and 23% for being overweight or obese, which is a little surprising, since the weight and obesity use case tends to get the most media attention. Then 3% fall into an &#8220;other&#8221; category. I think that&#8217;s where a lot of the noise around vanity use, people using it just to look better, is probably getting lumped in, but I&#8217;d expect that number to be higher than 3% if it were captured accurately.<\/p>\n<p class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\" data-sourcepos=\"103:1-103:310;15839-16148\"><strong>Geoff:<\/strong> Yeah, at the risk of drawing a direct parallel between GLP-1s and our favorite topic, AI, they both seem to have a real place in popular culture and are highly relevant whether you&#8217;re thinking about it personally or through the eyes of an employer trying to figure out coverage for their workforce.<\/p>\n<p class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\" data-sourcepos=\"105:1-105:697;16150-16846\">KFF is all over this too. A couple of stats from the Peterson-KFF Health System Tracker: just under 19% of firms with over 200 employees actually cover GLP-1s for weight loss. Definitely more coverage among larger companies, but right around 20% for mid-size businesses. And when you think about the gatekeeper programs, what employees need to do to get access, typically some type of clinical support or lifestyle and nutrition course, about one in three firms require that, which is probably a bit lower than either of us would have expected. So any time there&#8217;s a newsworthy announcement like this that could impact accessibility of these drugs, everyone in this space is going to take notice.<\/p>\n<p class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\" data-sourcepos=\"107:1-107:506;16848-17353\"><strong>Nick:<\/strong> Agreed. So, onto the topic. Last week, the FDA announced a crackdown on active pharmaceutical ingredients found in GLP-1s. That matters because demand for this drug class has been so high that a huge direct-to-consumer market has formed, both from pharmaceutical companies like Novo Nordisk and from compound pharmacies filling the gap where demand exceeds supply. That was especially true 12 to 24 months ago; supply chains have caught up somewhat since, but it&#8217;s still not an easy drug to get.<\/p>\n<p class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\" data-sourcepos=\"109:1-109:480;17355-17834\">I didn&#8217;t even know exactly what a compound pharmacy was going into this. Apparently, compound pharmacies are allowed to operate without FDA approval in two main scenarios. One is customizing medication: if someone can&#8217;t take a pill, for example, a compounder might create a different dose or a cream designed to do the same thing as an FDA-approved product for an individualized case. The other, and the bigger market in some cases, is stepping in when there&#8217;s a supply shortage.<\/p>\n<p class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\" data-sourcepos=\"111:1-111:433;17836-18268\">Early in GLP-1 history, Novo Nordisk was the only company with an approved option: Ozempic, the injection. People often use &#8220;Ozempic&#8221; and &#8220;GLP-1&#8221; interchangeably. Now there&#8217;s also Wegovy, Novo Nordisk&#8217;s pill format, which is currently the only FDA-approved oral GLP-1 pill on the market. There are others in the FDA approval pipeline for the obesity use case, and I believe another approved for diabetes but not yet for weight loss.<\/p>\n<p class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\" data-sourcepos=\"113:1-113:831;18270-19100\">Companies like Hims &amp; Hers, a very well-known, multi-billion-dollar publicly traded compound pharmacy operating through telemedicine, recognized this demand and entered the market, starting with a compounded injection and preparing to launch a pill. But the FDA removed the relevant ingredients from the approved compounding list. If an ingredient is on that list, you can produce it without FDA approval. The moment it comes off, you need approval to continue. That directly disrupts the Hims &amp; Hers weight-loss business. They&#8217;ve already announced they won&#8217;t bring their planned pill to market, and there are strong rumors they may pull their injection too. I don&#8217;t see how they avoid that if the ingredient in that product is the one that came off the list. Either way, this removes real supply that people have been relying on.<\/p>\n<p class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\" data-sourcepos=\"115:1-115:577;19102-19678\"><strong>Geoff:<\/strong> And Hims &amp; Hers is the focal point of this particular FDA crackdown, but they&#8217;re not the only compound pharmacy affected. The ripple effects extend further: if certain ingredients in GLP-1s or semaglutides are no longer FDA-approved for compounding, you&#8217;re not looking at a viable product to bring to market anymore. Companies either have to re-engineer their offerings or temporarily halt planned releases, and that has to affect availability in the consumer market, a market that&#8217;s often been more affordable than paying out of pocket even with employer coverage.<\/p>\n<p class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\" data-sourcepos=\"117:1-117:697;19680-20376\">So the question becomes: what&#8217;s the reaction from the broader workforce? Is the pressure that already exists on employers to cover these drugs going to intensify? And if employers do start seriously considering coverage, are they going to follow the roughly one-third of companies that currently require a lifestyle management or clinical condition support program before granting access? In that same Health System Tracker data, two-thirds of firms say GLP-1 coverage has moderately or significantly impacted their prescription drug spending. Employers need to weigh whether they&#8217;re prepared to take on that kind of expense, and if so, whether they pair it with some form of program requirement.<\/p>\n<p class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\" data-sourcepos=\"119:1-119:549;20378-20926\"><strong>Nick:<\/strong> That one-third stat surprised me too. I would have guessed more employers would require a program, for two reasons. Employers are thinking about GLP-1s in two ways right now. One group sees the increased pharmacy spend as an investment: yes, costs go up, but they expect to see the benefit downstream through better management of diabetes, heart disease, and weight loss. The other group is looking at the same pharmacy spend increase and thinking about how to create a hurdle, like a lifestyle management program, before granting access.<\/p>\n<p class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\" data-sourcepos=\"121:1-121:991;20928-21918\">I don&#8217;t think cost control should be the primary reason to build one of these programs, because lifestyle management programs genuinely serve a purpose. You can get a decent outcome just from taking a GLP-1 and doing nothing else. But if you provide nutrition support tailored to someone on the drug, and resources around physical activity, since this level of weight loss comes with muscle loss as well as fat loss, you turn a good outcome into the best possible one. So knowing that, I expect more than a third of employers to adopt these programs going forward: some purely to manage cost, but others because they&#8217;re chasing the best outcome for their people. My guess is the low adoption so far comes down to complexity. Rolling out a new drug benefit and a companion program at the same time is a lot to digest at once. I&#8217;d expect some employers who already cover the drug to come back later and add a program on top of it, framing it as a benefit to both the company and the employee.<\/p>\n<p class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\" data-sourcepos=\"123:1-123:461;21920-22380\"><strong>Geoff:<\/strong> And the benefit to the employee is really about mindset. Beyond supporting healthy weight for its own sake, this is also a satisfaction play. That same KFF report found that for employers currently covering GLP-1s for weight loss, that coverage is rated important or very important for employee satisfaction. And again, that data predates any potential crunch on consumer accessibility. So the pressure on employers is only going to build from here.<\/p>\n<p class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\" data-sourcepos=\"125:1-125:471;22382-22852\"><strong>Nick:<\/strong> No doubt. That&#8217;s one of the things I find so interesting about this industry. We spend so much time thinking about how to move the needle on people&#8217;s health, on productivity, on healthcare costs. But sometimes it&#8217;s simply a demand issue: employees want it, so employers move to provide it, regardless of the broader ecosystem of research and reasoning behind it. It&#8217;s another example of ending up in the right place, but not always for the reason you&#8217;d expect.<\/p>\n<p class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\" data-sourcepos=\"127:1-127:859;22854-23712\">One stat I always come back to on GLP-1s: there&#8217;s a Jefferies study, and I&#8217;ll use their more conservative estimate, projecting that domestic US airlines will save around $580 million annually in fuel costs as GLP-1 adoption continues, simply because the average total weight of passengers on a plane goes down. Their estimate was that a 10% reduction in average passenger weight could lead to a 1.5% reduction in fuel costs. Given that airlines spend tens of billions of dollars annually on fuel, even a small percentage reduction translates into hundreds of millions of dollars in additional profit. And that comes from airlines doing absolutely nothing differently. No lighter planes, no operational changes, no fuel-efficiency improvements from manufacturers. Something happening entirely in healthcare is having a massive impact on an unrelated industry.<\/p>\n<p class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\" data-sourcepos=\"129:1-129:771;23714-24484\">Honestly, if AI weren&#8217;t the business story of the day, every single day, I think GLP-1s would be the number one story. I&#8217;d go further and say that over the next two to four years, the impact of GLP-1s on the country and the economy could exceed the impact of AI, at least in that window. AI may have a bigger impact in the long run, potentially replacing jobs or reshaping the workforce in ways that aren&#8217;t always desirable. But today, we&#8217;re seeing businesses with nothing to do with healthcare feel meaningful effects from the GLP-1 movement. And we&#8217;re still early. Only 19% of companies cover it. Only 18% of people have used it, and 12% are currently using it. That&#8217;s a huge number of people who could eventually be on a drug like this with real, meaningful benefits.<\/p>\n<p class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\" data-sourcepos=\"131:1-131:453;24486-24938\"><strong>Geoff:<\/strong> Well, it sounds like you and I are going to have plenty to talk about over the next few years. Hopefully airline ticket prices come down with all those fuel savings, though I wouldn&#8217;t count on it. That seems like a great place to wrap up. Thanks, as always, to those tuning in. Feel free to subscribe to Wellable Weekly on Apple, Spotify, or wherever you get your podcasts, and be sure to check out the Wellable Weekly newsletter. Thank you.<\/p>\n          <\/div>\n        <\/div>\n\n        \n      <\/div>\n    <\/section>\n\n    \n","protected":false},"excerpt":{"rendered":"<p>Wellable Weekly unpack the FDA&#8217;s GLP-1 crackdown on compound pharmacies, new adoption data, and what it means for employer benefits and pharmacy spend.<\/p>\n","protected":false},"author":1,"featured_media":35152,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[23],"tags":[],"class_list":["post-35153","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-podcasts"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.6 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>FDA Crackdowns Shaping the GLP-1 Market | Wellable<\/title>\n<meta name=\"description\" content=\"Wellable Weekly unpack the FDA&#039;s GLP-1 crackdown on compound pharmacies, new adoption data, and what it means for employer benefits and pharmacy spend.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.wellable.co\/blog\/fda-crackdowns-shaping-the-glp-1-market\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Crackdowns Shaping the GLP-1 Market | Wellable\" \/>\n<meta property=\"og:description\" content=\"Wellable Weekly unpack the FDA&#039;s GLP-1 crackdown on compound pharmacies, new adoption data, and what it means for employer benefits and pharmacy spend.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.wellable.co\/blog\/fda-crackdowns-shaping-the-glp-1-market\/\" \/>\n<meta property=\"og:site_name\" content=\"Wellable\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/GetWellable\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-25T14:12:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-31T13:14:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.wellable.co\/blog\/wp-content\/uploads\/2026\/07\/FDA-Crackdowns-Shaping-the-GLP-1-Market.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wellable\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@getwellable\" \/>\n<meta name=\"twitter:site\" content=\"@getwellable\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wellable\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA Crackdowns Shaping the GLP-1 Market | Wellable","description":"Wellable Weekly unpack the FDA's GLP-1 crackdown on compound pharmacies, new adoption data, and what it means for employer benefits and pharmacy spend.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.wellable.co\/blog\/fda-crackdowns-shaping-the-glp-1-market\/","og_locale":"en_US","og_type":"article","og_title":"FDA Crackdowns Shaping the GLP-1 Market | Wellable","og_description":"Wellable Weekly unpack the FDA's GLP-1 crackdown on compound pharmacies, new adoption data, and what it means for employer benefits and pharmacy spend.","og_url":"https:\/\/www.wellable.co\/blog\/fda-crackdowns-shaping-the-glp-1-market\/","og_site_name":"Wellable","article_publisher":"https:\/\/www.facebook.com\/GetWellable\/","article_published_time":"2026-02-25T14:12:00+00:00","article_modified_time":"2026-07-31T13:14:44+00:00","og_image":[{"width":1280,"height":720,"url":"https:\/\/www.wellable.co\/blog\/wp-content\/uploads\/2026\/07\/FDA-Crackdowns-Shaping-the-GLP-1-Market.jpg","type":"image\/jpeg"}],"author":"Wellable","twitter_card":"summary_large_image","twitter_creator":"@getwellable","twitter_site":"@getwellable","twitter_misc":{"Written by":"Wellable","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.wellable.co\/blog\/fda-crackdowns-shaping-the-glp-1-market\/#article","isPartOf":{"@id":"https:\/\/www.wellable.co\/blog\/fda-crackdowns-shaping-the-glp-1-market\/"},"author":{"name":"Wellable","@id":"https:\/\/www.wellable.co\/blog\/#\/schema\/person\/f7c042b5403e555f4cd545a365023e71"},"headline":"FDA Crackdowns Shaping the GLP-1 Market","datePublished":"2026-02-25T14:12:00+00:00","dateModified":"2026-07-31T13:14:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.wellable.co\/blog\/fda-crackdowns-shaping-the-glp-1-market\/"},"wordCount":1483,"publisher":{"@id":"https:\/\/www.wellable.co\/blog\/#organization"},"image":{"@id":"https:\/\/www.wellable.co\/blog\/fda-crackdowns-shaping-the-glp-1-market\/#primaryimage"},"thumbnailUrl":"https:\/\/www.wellable.co\/blog\/wp-content\/uploads\/2026\/07\/FDA-Crackdowns-Shaping-the-GLP-1-Market.jpg","articleSection":["Podcasts"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.wellable.co\/blog\/fda-crackdowns-shaping-the-glp-1-market\/","url":"https:\/\/www.wellable.co\/blog\/fda-crackdowns-shaping-the-glp-1-market\/","name":"FDA Crackdowns Shaping the GLP-1 Market | Wellable","isPartOf":{"@id":"https:\/\/www.wellable.co\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.wellable.co\/blog\/fda-crackdowns-shaping-the-glp-1-market\/#primaryimage"},"image":{"@id":"https:\/\/www.wellable.co\/blog\/fda-crackdowns-shaping-the-glp-1-market\/#primaryimage"},"thumbnailUrl":"https:\/\/www.wellable.co\/blog\/wp-content\/uploads\/2026\/07\/FDA-Crackdowns-Shaping-the-GLP-1-Market.jpg","datePublished":"2026-02-25T14:12:00+00:00","dateModified":"2026-07-31T13:14:44+00:00","description":"Wellable Weekly unpack the FDA's GLP-1 crackdown on compound pharmacies, new adoption data, and what it means for employer benefits and pharmacy spend.","breadcrumb":{"@id":"https:\/\/www.wellable.co\/blog\/fda-crackdowns-shaping-the-glp-1-market\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.wellable.co\/blog\/fda-crackdowns-shaping-the-glp-1-market\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.wellable.co\/blog\/fda-crackdowns-shaping-the-glp-1-market\/#primaryimage","url":"https:\/\/www.wellable.co\/blog\/wp-content\/uploads\/2026\/07\/FDA-Crackdowns-Shaping-the-GLP-1-Market.jpg","contentUrl":"https:\/\/www.wellable.co\/blog\/wp-content\/uploads\/2026\/07\/FDA-Crackdowns-Shaping-the-GLP-1-Market.jpg","width":1280,"height":720,"caption":"FDA Crackdowns Shaping the GLP-1 Market"},{"@type":"BreadcrumbList","@id":"https:\/\/www.wellable.co\/blog\/fda-crackdowns-shaping-the-glp-1-market\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.wellable.co\/blog\/"},{"@type":"ListItem","position":2,"name":"FDA Crackdowns Shaping the GLP-1 Market"}]},{"@type":"WebSite","@id":"https:\/\/www.wellable.co\/blog\/#website","url":"https:\/\/www.wellable.co\/blog\/","name":"Wellable","description":"Latest Research &amp; News in Wellness","publisher":{"@id":"https:\/\/www.wellable.co\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.wellable.co\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.wellable.co\/blog\/#organization","name":"Wellable","url":"https:\/\/www.wellable.co\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.wellable.co\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/www.wellable.co\/blog\/wp-content\/uploads\/2022\/06\/favicon-wellable.webp","contentUrl":"https:\/\/www.wellable.co\/blog\/wp-content\/uploads\/2022\/06\/favicon-wellable.webp","width":155,"height":157,"caption":"Wellable"},"image":{"@id":"https:\/\/www.wellable.co\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/GetWellable\/","https:\/\/x.com\/getwellable","https:\/\/www.linkedin.com\/company\/wellable-inc-\/","https:\/\/www.youtube.com\/channel\/UCtTLlvZR-tKRBcb32l-rFXg"]},{"@type":"Person","@id":"https:\/\/www.wellable.co\/blog\/#\/schema\/person\/f7c042b5403e555f4cd545a365023e71","name":"Wellable","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/acf8de6b4e70889e608d47410dcdc1ac0fea5050a1d89c468bea5ae977f4eda7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/acf8de6b4e70889e608d47410dcdc1ac0fea5050a1d89c468bea5ae977f4eda7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/acf8de6b4e70889e608d47410dcdc1ac0fea5050a1d89c468bea5ae977f4eda7?s=96&d=mm&r=g","caption":"Wellable"},"sameAs":["http:\/\/34.168.145.72"],"url":"https:\/\/www.wellable.co\/blog\/author\/wellable-admin\/"}]}},"jetpack_featured_media_url":"https:\/\/www.wellable.co\/blog\/wp-content\/uploads\/2026\/07\/FDA-Crackdowns-Shaping-the-GLP-1-Market.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.wellable.co\/blog\/wp-json\/wp\/v2\/posts\/35153","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wellable.co\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wellable.co\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wellable.co\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wellable.co\/blog\/wp-json\/wp\/v2\/comments?post=35153"}],"version-history":[{"count":10,"href":"https:\/\/www.wellable.co\/blog\/wp-json\/wp\/v2\/posts\/35153\/revisions"}],"predecessor-version":[{"id":35163,"href":"https:\/\/www.wellable.co\/blog\/wp-json\/wp\/v2\/posts\/35153\/revisions\/35163"}],"wp:attachment":[{"href":"https:\/\/www.wellable.co\/blog\/wp-json\/wp\/v2\/media?parent=35153"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wellable.co\/blog\/wp-json\/wp\/v2\/categories?post=35153"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wellable.co\/blog\/wp-json\/wp\/v2\/tags?post=35153"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}